Anti-CoV-RBD (A2) antibody from ProteoGenix; catalogue PTXCOV-A521D; research use only.
Know who made it. See the evidence. Buy through one marketplace.
The anti-CoV-RBD (A2) antibody is a fully human IgG immunoglobulin designed to target the receptor-binding domain (RBD) of the new pandemic strain of coronavirus, SARS-CoV-2. Targeting this specific domain presents unique advantages when it comes to the development of COVID-19 therapeutic antibodies.
The RBD is responsible for recognizing and binding the specific cell surface marker ACE2 (angiotensin-converting enzyme 2). This interaction further leads to the proteolytic cleavage of the spike exposing the S2 subunit and initiating the formation of the membrane fusion core complex. Antibodies able to block this initial interaction are known as neutralizing antibodies (NAbs). These specific and rare antibodies are on the vanguard of COVID-19 treatments due to their ability to arrest SARS-CoV-2 infections in their earliest stages.
This new antibody was obtained by screening a high-diversity COVID-19 human antibody library (LiAb-SFCOVID-19™) using phage display technology (i.e. biopanning) and recombinantly expressed RBD as the desired target. It capitalizes on the immune repertoire developed in patients who have been infected with COVID-19. Additionally, the specificity and affinity of the newly developed molecule were tested in the ELISA platform. Its stability and ease of production were further confirmed by consistently obtaining high production yields in XtenCHO™, a transient mammalian system based on an engineered variant of CHO.
Moreover, the neutralizing activity of antibody R3P2-A2 was confirmed in vitro through the indirect detection assay: SARS-CoV-2 Surrogate Virus Neutralization kit. The assay works on the principle of direct competition between candidate antibodies and the ACE2 for the binding pocket of RBD. This antibody and other similar products serve as effective research tools to either detect the presence of SARS-CoV-2 in multiple samples in ELISA tests, as well as to potentially better understand the mechanism of infection in the new coronavirus.
ProteoGenix catalogue number PTXCOV-A521D. For research use only.
Target: RBD domain- SARS-CoV2 Spike protein; Clonality: Monoclonal Antibody; Expression system: Mammalian; Purity: 85%; Molecular weight: 150kDa; Buffer: PBS, pH7,5.
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
